Market research
ATOS Atossa Genetics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 18.6667
- Dividend yield
- Not available
- Beta
- 1.25
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US04962H7044
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 18.6667
- Dividend yield
- Not available
- Beta
- 1.25
About
About Atossa Genetics Inc
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ATOS discussion.
5 years, 4 months ago
Atossa Therapeutics, Inc is currently in a long term uptrend where the price is trading 115.6% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Atossa Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 185.8% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 26.4% to $-3M since the same quarter in the previous year.
Based on the above factors, Atossa Therapeutics, Inc gets an overall score of 2/5.